SK Chemicals and Eisai Korea Sign Co-Promotion Agreement for Dayvigo, Korea's First 'Orexin Blockade' Insomnia Drug
SK Chemicals and Eisai Korea have joined forces ahead of the domestic launch of "Dayvigo," the country's first insomnia treatment based on the 'orexin blockade' mechanism.
On July 1, SK Chemicals announced that it had signed a co-promotion agreement with Eisai Korea for the insomnia medication Dayvigo.
Hyunsun Park, Head of Pharma Business at SK Chemicals (right), and Hongbyung Ko, CEO of Eisai Korea (left), are taking a commemorative photo after signing the contract. SK Chemicals
View original imageUnder this agreement, SK Chemicals will be responsible for promotional activities at hospitals and clinics with fewer than 300 beds, while Eisai Korea will handle promotion at medical institutions with 300 or more beds. Nationwide distribution of Dayvigo will be managed exclusively by SK Chemicals.
Dayvigo is an insomnia medication in the Dual Orexin Receptor Antagonist (DORA) class, containing the active ingredient lemborexant. After the U.S. FDA approved Dayvigo based on the results of global Phase 3 clinical trials conducted on adults with insomnia, it has been used in countries such as the United States, Japan, Canada, and Singapore. Currently, most insomnia treatments in Korea are in the class of hypnotic sedatives. Dayvigo is expected to be officially launched in Korea in the second half of this year as the country's first DORA-class insomnia medication.
Unlike conventional hypnotic sedatives, Dayvigo is a medication that induces sleep by targeting arousal neurotransmitters. Orexin, the target of Dayvigo, is a neurotransmitter that helps maintain wakefulness in the brain. While existing hypnotic sedatives induce sleep mainly through sedative effects, Dayvigo works by blocking orexin from binding to its receptors, thereby reducing excessive arousal signals. While traditional treatments for insomnia, considered a state of hyperarousal, have focused on enhancing sedation, Dayvigo is drawing attention as a medication that directly suppresses hyperarousal and more directly supports sleep maintenance.
In the global Phase 3 study "SUNRISE 1," which evaluated the efficacy and safety of Dayvigo in 1,006 insomnia patients aged 55 and older, the Dayvigo group showed improvements in time to fall asleep and sleep maintenance indicators compared to placebo and zolpidem extended-release groups. In the "SUNRISE 2" study involving adult insomnia patients, Dayvigo also showed improvements in sleep-related indicators compared to placebo when administered for more than six months, and this effect was observed for up to 12 months.
As the number of patients seeking medical care for sleep disorders continues to rise, the market for insomnia treatments is also steadily growing. According to the pharmaceutical market research firm IQVIA, the domestic insomnia treatment market grew from 48 billion won in 2021 to 81.8 billion won in 2025. Over four years, the market increased by 70.4%, with an average annual growth rate of 14.3%.
According to data from the Health Insurance Review & Assessment Service, the number of patients who received health insurance-covered treatment for sleep disorders increased from approximately 1.03 million in 2020 to 1.3 million in 2024. Both companies plan to actively collaborate for the successful launch and market expansion of the new insomnia drug Dayvigo.
Hongbyung Ko, CEO of Eisai Korea, stated, "Dayvigo is the first DORA-class treatment to be introduced in Korea. As a therapy that targets sleep neurotransmission, it will shift the paradigm of insomnia treatment. SK Chemicals is a partner with extensive sales and marketing capabilities, strong customer access, and strict compliance standards in the field of neurological disorder treatments. We expect them to play a key role in establishing Dayvigo in the domestic market."
Hyunseon Park, Head of Pharma Business at SK Chemicals, said, "The number of patients with sleep disorders has grown at an average annual rate of about 6%, and among them, insomnia is a condition that directly affects quality of life by impacting normal daytime activities, beyond being a mere symptom. By leveraging SK Chemicals' extensive nationwide hospital and clinic network, we will improve patient access to insomnia treatments and focus our expertise and marketing capabilities in neurology to contribute to the successful establishment of Dayvigo."
Dayvigo is available in 5 mg and 10 mg doses. It received product approval from the Ministry of Food and Drug Safety on June 23 and is expected to be launched in Korea in the second half of this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Eisai Korea is the Korean subsidiary of global pharmaceutical company Eisai Co., Ltd., founded in Tokyo in 1941. Since its entry into the Korean market in 1997, the company has established itself as a global R&D-focused pharmaceutical company with strengths in Alzheimer's disease, Parkinson's disease, epilepsy, oncology, and autoimmune diseases.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.